Cholelithiasis Associated With Common Bile Duct Stones
Conditions
Keywords
Cholelithiasis with Concomitant Choledocholithiasis, Endoscopic Transpapillary Gallbladder-preserving Cholecystolithotomy, ERCP plus Laparoscopic Cholecystectomy, Conservative treatment
Brief summary
Recruit patients with cholelithiasis with concomitant choledocholithiasis into the cohort, and assign them to undergo endoscopic transpapillary gallbladder-preserving cholecystolithotomy or ERCP plus laparoscopic cholecystectomy or conservative treatment based on patient preference. Collect clinical data and patient-reported outcomes regularly at baseline and during follow-up in the cohort. Assess the clinical safety of ERCP-GPC and LC by evaluating the clinical success rate of treatment as well as the incidence of short-term and long-term postoperative complications; investigate the efficacy differences among endoscopic transpapillary gallbladder-preserving cholecystolithotomy or ERCP plus laparoscopic cholecystectomy or conservative treatment in managing cholelithiasis with concomitant choledocholithiasis.
Interventions
Based on the patient's preference, they will receive the following treatment:endoscopic transpapillary gallbladder-preserving
Based on the patient's preference, they will receive the following treatment:ERCP plus Laparoscopic Cholecystectomy
Based on the patient's preference, they will receive the following treatment:ursodeoxycholic acid for stone dissolution,ESWL or symptomatic and supportive care.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Patients over the age of 18 years; 2. Ultrasound, MRCP, or other imaging examination findings (CT/MRI) clearly indicate a diagnosis of cholelithiasis with concomitant choledocholithiasis; 3. Patients with no history of gastrointestinal reconstruction surgery or cholecystectomy or previous biliary tract surgery (include history of ERCP); 4. Patients with every gallbladder stone ≤1 cm in diameter or sludge-like stones; 5. The morphology and size of the gallbladder are essentially normal and the thickness of the gallbladder wall is ≤3 mm; 6. Voluntary provision of signed informed consent.
Exclusion criteria
1. Atrophic cholecystitis; porcelain gallbladder; suspect malignant tumor of the gallbladder; stenosis of the lower segment of the common bile duct; Mirrizzi syndrome; 2. Unable to undergo endoscopic interventions for various reasons; 3. Absolute surgical contraindications, including severe hepatic, renal, cardiac and pulmonary insufficiency, history of cerebral coma and allergy to anesthesia, etc; 4. Presence of ectopic duodenal papilla or congenital pancreaticobiliary malformation; 5. Patients with severe coagulopathy, defined as an International Normalized Ratio (INR) \> 1.5 or patients with significant thrombocytopenia (platelet count \< 50 × 10⁹/L); 6. Pregnant women;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assess the clinical safety of ERCP-GPC ,LC and conservative treatments by evaluating the incidence of intraoperative,short-term and long-term postoperative complications. | From enrollment to 3 years after the end of treatment | Compare the rates of intraoperative, early, and late postoperative complications include bile duct injury and recurrence of bile duct stones,etc. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Investigate the differences in efficacy among endoscopic transpapillary gallbladder-preserving cholecystolithotomy , ERCP plus laparoscopic cholecystectomy and conservative treament in managing cholelithiasis with concomitant choledocholithiasis. | From enrollment to 3 years after the end of treatment | Compare the gallbladder stone clearance rate and bile duct stone clearance rate among the three groups; meanwhile, record the rates of successful gallbladder access establishment via FCMS and successful guidewire cannulation into the gallbladder in the gallbladder-preserving cholecystolithotomy group, so as to clarify the clinical success rate and technical success rate of this technique. |
| Conduct a comparative analysis of the economic efficiency of ERCP-GPC , LC and conservative treatment. | From enrollment to 3 years after the end of treatment | Record duration of Hospitalization and total Medical Expenses of the three groups then calculate them as total medical expenses / duration of hospitalization (Unit: \[e.g., CNY/USD\] per day).It can reflect the average daily inpatient economic cost for each treatment, enabling integrated comparison of economic efficiency across the three groups. |
Countries
China
Contacts
Qilu Hospital of Shandong University